The current results showed that a diagnosis of macrovascular disease and renal disease were associated with prescription of DPP-4 inhibitors rather than metformin, while diagnosis of a microvascular complication was associated with the prescription of metformin over DPP-4 inhibitors as the index T2DM treatment. Here, DPP4 is linked to kidney disorder.